Table 1.

Clinical data of the study cohort (baseline characteristics and outcomes of each individual of the study cohort).

Baseline characteristics									Outcomes
Patient ID*	Age (a)	Sex	Disease course	Disease duration (a)	Previous disease activity (relapses/2a)	Previous DMT	Delay from previous DMT (d)	EDSS at baseline	Disease activity (1: MRI, 2: MRI + relapse)	Lymphopenia (<700/µl in first year)	GI symptoms	Flushing
1	36	m	RRMS	0.3	0	None	-	1.0	0	0	0	1
2	38	m	RRMS	0.2	2	None	-	2.0	0	0	0	0
3	45	f	RRMS	3.8	0	Daclizumab	27	2.0	0	1	0	1
4	59	f	RRMS	3.4	0	Fingolimod	104	3.5	0	1	0	0
5	54	f	RRMS	8.1	0	Glatirameracetate	12	3.0	0	0	1	1
6	43	m	RRMS	2.3	0	Teriflunomide	53	2.0	0	1	1	1
7	50	f	RRMS	11.7	0	Interferon beta	546	2.5	0	1	0	1
9	57	f	RRMS	0.9	2	None	-	3.0	0	1	0	0
10	40	f	RRMS	0.3	1	None	-	1.5	0	1	0	0
13	32	m	RRMS	0.4	1	None	-	1.0	2	0	0	0
14	23	m	RRMS	0.2	1	None	-	2.0	1	0	0	1
15	42	m	RRMS	0.2	2	None	-	3.0	0	0	1	1
16	37	f	RRMS	7.4	1	Teriflunomide	74	1.5	0	1	1	1
17	44	m	RRMS	10.2	0	Fingolimod	115	4.0	0	0	0	0
19	30	m	RRMS	0.1	2	None	-	2.0	0	0	0	0
21	49	f	RRMS	0.1	1	Glatirameracetate	16	1.5	2	1	0	0
25	34	m	RRMS	1.0	0	Glatirameracetate	17	0.0	1	0	0	0
27	27	f	RRMS	6.5	4	Teriflunomide	62	3.0	0	0	0	1
29	50	f	RRMS	10.6	0	Glatirameracetate	5	1.0	1	1	0	0
33	41	f	RRMS	0.1	1	None	-	2.5	0	0	0	0